fumarate
Small moleculeexperimental
Fumaric acid or trans-butenedioic acid is an organic compound with the formula HO2CCH=CHCO2H. A white solid, fumaric acid occurs widely in nature. It has a fruit-like taste and has been used as a food additive. Its E number is E297. The salts and esters are known as fumarates. Fumarate can also refer to the C4H2O2−4 ion (in solution). Fumaric acid is the trans isomer of butenedioic acid, while maleic acid is the cis isomer. — Wikipedia
Clinical trial activity
6 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
3
Phase 4
1
Earliest trial started Jul 1, 2001 (NCT00034905)
Timeline
Indications
Approved for
Mechanism of action
- Unspecified targetUnclear
Unclear
Chemistry & pharmacology
Loading structure…
SMILES
O=C(O)/C=C/C(=O)O- Mol. weight
- 116.07 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaFumaric acid ↗
- ChEMBLCHEMBL503160 ↗
Also known as
- (2e)-2-butenedioic acid
- (2e)-2-butenedioic acid
- 2-(e)-butenedioic acid
- allomaleic acid
- ammonium fumarate
- e297
- e297
- (e)-2-butenedioic acid
- (e)-2-butenedioic acid
- fumarate
- fumarate
- fumaric acid
- fumaric acid
- fumaric acid
- fumaric acid
- fumaric acid
- fumaric acid
- fumaric acid
- fumaric acid
- fumaricum acidum
- fumaricum acidum
- fumarsäure
- fumarsäure
- furamag
- furamag
- magnesium fumarate
- sodium fumarate
- trans-1,2-ethylenedicarboxylic acid
- trans-1,2-ethylenedicarboxylic acid
- trans-but-2-enedioic acid
- trans-but-2-enedioic acid
- trans-butenedioic acid
- trans-butenedioic acid
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02955693 | Phase 1 | Sep 1, 2016 | Almirall |
| NCT01815723 | Phase 3 | Jun 1, 2016 | Forward Pharma GmbH, Probity Medical Research |
| NCT02671162 | Phase 2 | Jul 1, 2015 | University of Tehran |
| NCT02474082 | Phase 3 | Apr 1, 2015 | Novartis |
| NCT00254774 | Phase 3 | Jan 1, 2002 | AstraZeneca |
| NCT00034905 | Phase 4 | Jul 1, 2001 | AstraZeneca |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 2 | 2 | 2 | 2001 |
| Almirall | For profit | 1 | 1 | 1 | 2016 |
| Forward Pharma GmbH | For profit | 1 | 1 | 1 | 2016 |
| Novartis | For profit | 1 | 1 | 1 | 2015 |
| Probity Medical Research | For profit | 1 | 0 | 1 | 2016 |
| University of Tehran | Academic/Hospital | 1 | 1 | 1 | 2015 |
6 organizations
Page 1 / 1